IFP Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Hold |
0
| – | – | – | 4047 |
|
|
2024
Q4 | – | Hold |
0
| – | – | – | 4340 |
|
|
2023
Q4 | – | Sell |
-75
| Closed | -$860 | – | 3387 |
|
|
2023
Q3 | $860 | Hold |
75
| – | – | ﹤0.01% | 3030 |
|
|
2023
Q2 | $1.9K | Sell |
75
-2,000
| -96% | -$62.3K | ﹤0.01% | 2897 |
|
|
2023
Q1 | $59.6K | Buy |
2,075
+2,000
| +2,667% | +$62.3K | ﹤0.01% | 1491 |
|
|
2022
Q4 | $2K | Sell |
75
-9
| -11% | -$206 | ﹤0.01% | 4246 |
|
|
2022
Q3 | $3K | Hold |
84
| – | – | ﹤0.01% | 4282 |
|
|
2022
Q2 | $3K | Hold |
84
| – | – | ﹤0.01% | 4048 |
|
|
2022
Q1 | $3K | Buy |
84
+9
| +12% | +$136 | ﹤0.01% | 4048 |
|
|
2021
Q4 | $1K | Buy |
+75
| New | +$1.25K | ﹤0.01% | 3159 |
|
|
2017
Q3 | – | Sell |
-1,250
| Closed | -$33K | – | 4240 |
|
|
2017
Q2 | $33K | Buy |
1,250
+250
| +25% | +$5.58K | ﹤0.01% | 2260 |
|
|
2017
Q1 | $21K | Buy |
+1,000
| New | +$20.5K | ﹤0.01% | 2487 |
|
|
2016
Q1 | – | Sell |
-7
| Closed | – | – | 3524 |
|
|
2015
Q4 | $0 | Buy |
+7
| New | +$243 | ﹤0.01% | 3807 |
|
Other funds holding RVNC
IFP Advisors's RVNC Position: Q1 2025 in Review
IFP Advisors held its Revance Therapeutics, Inc. (RVNC) position steady in Q1 2025 at 0 shares worth $44. The position accounts for ﹤0.01% of the portfolio, ranked #4047.
IFP Advisors first reported a position in RVNC in Q4 2015 and has held it in 11 quarters since. The position peaked at $59.6K in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- IFP Advisors held 0 shares of Revance Therapeutics, Inc. worth $44 as of Q1 2025.
- IFP Advisors left its Revance Therapeutics, Inc. share count unchanged in Q1 2025.
- Revance Therapeutics, Inc. made up ﹤0.01% of IFP Advisors's portfolio in Q1 2025, its #4047 holding.
- IFP Advisors first reported a position in Revance Therapeutics, Inc. in Q4 2015 and has held it in 11 quarters since.
- IFP Advisors's Revance Therapeutics, Inc. position peaked at $59.6K in Q1 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on IFP Advisors's 13F filing for Q1 2025, filed 5 May 2025.